Cited 5 times in
Prevalence, clinical significance, and persistence of autoantibodies in COVID-19
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구남수 | - |
dc.contributor.author | 김정호 | - |
dc.contributor.author | 안진영 | - |
dc.contributor.author | 염준섭 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 정수진 | - |
dc.contributor.author | 최준용 | - |
dc.contributor.author | 이세주 | - |
dc.contributor.author | 하장우 | - |
dc.contributor.author | 김진남 | - |
dc.contributor.author | 이기현 | - |
dc.contributor.author | 이정아 | - |
dc.date.accessioned | 2024-01-03T01:47:38Z | - |
dc.date.available | 2024-01-03T01:47:38Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197660 | - |
dc.description.abstract | Background: Interest in complications and sequelae following Coronavirus disease 2019 (COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune diseases and the association between autoantibodies and the severity of COVID-19. Thromboembolic complications are frequent in patients with COVID-19, and the anti-phospholipid antibodies (aPL) is frequently detected. We conducted this study to investigate the prevalence, clinical significance, and persistence of anti-nuclear antibodies (ANA) and aPLs in COVID-19. Methods: We enrolled patients diagnosed with COVID-19 with oxygen demand and admitted to a tertiary hospital in South Korea between July 2020 and March 2022. ANA and aPLs levels were assessed using an immunoassay kit. Results: A total of 248 patients were enrolled in the study. Among them, five patients were ANA-positive, and 41 were aPL-positive (IgM anti-cardiolipin (aCL) antibody in seven patients, IgG aCL in seven patients, IgM anti-β2Glycoprotein1 antibody (aβ2-GPI) in 32 patients, and IgG aβ2-GPI in one patient). Two of five ANA-positive patients, 13 of 32 IgM aβ2-GPI-positive patients, 5 of 7 IgM aCL-positive patients, and 2 of 7 IgG aCL-positive patients were eligible for follow-up analysis, and 100%, 69.2%, 40%, and 50% of the patients remained autoantibody-positive, respectively. There were no differences in clinical outcomes between the autoantibody-positive and autoantibody-negative groups, except for the IgG aCL group showing a tendency for worse outcomes. Conclusion: A significant proportion of COVID-19 patients with oxygen demand were autoantibody-positive, and autoantibodies persisted for several months after symptom onset. Whether these autoantibodies are related to long-term sequelae in COVID-19 patients requires further investigation. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | VIROLOGY JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antibodies, Anticardiolipin | - |
dc.subject.MESH | Autoantibodies* | - |
dc.subject.MESH | COVID-19* / epidemiology | - |
dc.subject.MESH | Clinical Relevance | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin G | - |
dc.subject.MESH | Immunoglobulin M | - |
dc.subject.MESH | Oxygen | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | beta 2-Glycoprotein I | - |
dc.title | Prevalence, clinical significance, and persistence of autoantibodies in COVID-19 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Se Ju Lee | - |
dc.contributor.googleauthor | Taejun Yoon | - |
dc.contributor.googleauthor | Jang Woo Ha | - |
dc.contributor.googleauthor | Jinnam Kim | - |
dc.contributor.googleauthor | Ki Hyun Lee | - |
dc.contributor.googleauthor | Jung Ah Lee | - |
dc.contributor.googleauthor | Chang Hyup Kim | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.contributor.googleauthor | Jung Ho Kim | - |
dc.contributor.googleauthor | Jin Young Ahn | - |
dc.contributor.googleauthor | Nam Su Ku | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Joon-Sup Yeom | - |
dc.contributor.googleauthor | Su Jin Jeong | - |
dc.identifier.doi | 10.1186/s12985-023-02191-z | - |
dc.contributor.localId | A00189 | - |
dc.contributor.localId | A00902 | - |
dc.contributor.localId | A02267 | - |
dc.contributor.localId | A02353 | - |
dc.contributor.localId | A02824 | - |
dc.contributor.localId | A03638 | - |
dc.contributor.localId | A04191 | - |
dc.relation.journalcode | J03383 | - |
dc.identifier.eissn | 1743-422X | - |
dc.identifier.pmid | 37845706 | - |
dc.subject.keyword | Anti-nuclear antibody | - |
dc.subject.keyword | Anti-phospholipid antibody | - |
dc.subject.keyword | Autoantibody | - |
dc.subject.keyword | COVID-19 | - |
dc.contributor.alternativeName | Ku, Nam Su | - |
dc.contributor.affiliatedAuthor | 구남수 | - |
dc.contributor.affiliatedAuthor | 김정호 | - |
dc.contributor.affiliatedAuthor | 안진영 | - |
dc.contributor.affiliatedAuthor | 염준섭 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.contributor.affiliatedAuthor | 정수진 | - |
dc.contributor.affiliatedAuthor | 최준용 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 236 | - |
dc.identifier.bibliographicCitation | VIROLOGY JOURNAL, Vol.20(1) : 236, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.